Form 4: NewAmsterdam Pharma Co N.V. Officer Kling Sells Shares Under 10b5-1 Plan

Douglas F. Kling, Chief Operating Officer of NewAmsterdam Pharma Co N.V., executed sales of ordinary shares on February 18 and 19, 2025, under a pre-arranged trading plan.

Summary

• Douglas F. Kling, the Chief Operating Officer of NewAmsterdam Pharma Co N.V., reported transactions involving the company's ordinary shares.
• On February 18, 2025, Kling exercised options to acquire 90,782 ordinary shares and sold the same amount.
• These shares were sold at prices ranging from $19.54 to $20.38 per share.
• On February 19, 2025, Kling exercised options to acquire 9,218 ordinary shares and sold the same amount.
• These shares were sold at prices ranging from $19.23 to $20.18 per share.
• The transactions were executed under a trading plan adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
• Following these transactions, Kling directly owns 44,000 ordinary shares.
• Kling also holds options to purchase 126,145 ordinary shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transactions are part of a pre-planned trading strategy and do not necessarily indicate a change in the officer's outlook on the company.

Industry Context

Insider selling can be interpreted in various ways by the market. While not inherently negative, large or frequent sales may raise concerns about management's confidence in the company's future prospects. However, sales under a 10b5-1 plan are often pre-scheduled and may not reflect a change in sentiment.

Stakeholder Impact

• Shareholders may react to the news of insider selling, although the pre-planned nature of the transactions may mitigate any negative impact.

Key Dates

Keywords

Form 4, Insider Trading, Share Sales, Option Exercise, Douglas F. Kling, NewAmsterdam Pharma Co N.V., NAMS, 10b5-1 plan